On the basis of these findings, we have proposed that a stable and highly active form of XCL1 could be used as a new adjuvant selectively activating cDC1s and also as a fusion partner of cancer antigens for cDC1-targeted cancer vaccines. This evidence concerns the gene XCL1 and cancer.